Wegovy Injection, Solution
NDC Package 0169-4501-14

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Wegovy (semaglutide) injection is semaglutide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. This formulation utilizes a injection, solution delivery system. Marketed by Novo Nordisk Pharmaceutical Industries, Lp, this product is identified by NDC 0169-4501 and is authorized under FDA application NDA215256.

Identification & Billing

NDC Package Code
0169-4501-14
Package Description
4 SYRINGE, PLASTIC in 1 CARTON / .5 mL in 1 SYRINGE, PLASTIC (0169-4501-01)
Product Code
0169-4501
11-Digit Billing Format
00169450114
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Wegovy
Non-Proprietary Name
Semaglutide
Substance Name
Semaglutide
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
SEMAGLUTIDE 1 mg/.5mL
Pharmacologic Class
Usage Information
Semaglutide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Semaglutide is also used in people with type 2 diabetes and heart disease to lower the risk of death from heart attack or stroke. Semaglutide is similar to a natural hormone in your body (incretin). It works by causing insulin release in response to high blood sugar (such as after a meal) and decreasing the amount of sugar your liver makes. If you use insulin, semaglutide is not a substitute for insulin treatment.

Regulatory & Marketing

Labeler Name
Novo Nordisk Pharmaceutical Industries, Lp
Product Type
Human Prescription Drug
FDA Application #
NDA215256
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
06-05-2021
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0169-4501-14 identifies a specific commercial package of 4 syringe, plastic in 1 carton / .5 ml in 1 syringe, plastic (0169-4501-01) of Wegovy, a human prescription drug labeled by Novo Nordisk Pharmaceutical Industries, Lp. This injection, solution is formulated for subcutaneous use and contains semaglutide as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Novo Nordisk Pharmaceutical Industries, Lp on June 05, 2021. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Semaglutide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Semaglutide is also used in people with type 2 diabetes and heart disease to lower the risk of death from heart attack or stroke. Semaglutide is similar to a natural hormone in your body (incretin). It works by causing insulin release in response to high blood sugar (such as after a meal) and decreasing the amount of sugar your liver makes. If you use insulin, semaglutide is not a substitute for insulin treatment.

How is this Novo Nordisk Pharmaceutical Industries, Lp product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00169450114. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0169-4501-14
11-Digit CMS (5-4-2)
00169-4501-14

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.